# US 2019/0376114 A1 · Diagnosis and monitoring of liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376114 A1
- Document ID: US20190376114A1
- Status: Published application
- Kind: A1
- Application number: 16/355,225
- Filed: 2019-03-15
- Published: 2019-12-12
- Earliest claimed: 2018-06-08
- Assignees: Glympse Bio, Inc.
- Applicants: Glympse Bio, Inc.
- Inventors: Sangeeta Bhatia; Gabriel Kwong; Eric Huang; Sirshendu Roopom Banerjee; Andrew Warren; Sophie Cazanave
- Web page: https://patentgrep.com/patent/US20190376114A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions for screening or diagnosis of liver disease are provided. The results may also indicate course and efficacy of treatment. The composition includes an activity sensor and a reporter releasably attached to the activity sensor. The method includes detecting the presence and/or amount of a reporter. The reporter is released from an activity sensor in the presence of diseased liver tissue but remains attached to the activity sensor in healthy tissue. The presence and/or amount of the reporter are used to characterize the liver disease. The liver disease may be nonalcoholic steatohepatitis (NASH) and results may further indicate staging of NASH.

## Claims

### Claim 1

A method for characterizing liver disease, the method comprising:
detecting a reporter that is released from an activity sensor differentially in diseased liver tissue versus healthy liver tissue; and
characterizing a liver disease based upon a presence and/or amount of said reporter.

### Claim 2 (depends on 1)

The method of claim 1, wherein said presence and/or amount is determined in a urine sample obtained from a patient to whom the activity sensor was administered.

### Claim 3 (depends on 1)

The method of claim 1, further comprising detecting a plurality of reporters from a plurality of activity sensors, wherein different ones of the plurality of reporters are released by enzymes that are differentially active in the diseased liver tissue versus the healthy liver tissue.

### Claim 4 (depends on 3)

The method of claim 3, wherein the enzymes differentially active in the diseased liver tissue comprise a set of enzymes wherein activity of the set has been shown to correlate to a stage of the liver disease.

### Claim 5 (depends on 3)

The method of claim 3, further comprising measuring quantities of the plurality of detected reporters.

### Claim 6 (depends on 3)

The method of claim 3, wherein each of the enzymes is a protease.

### Claim 7 (depends on 3)

The method of claim 3, further comprising correlating quantities of the plurality of detected reporters to a rate of progression or regression of the liver disease.

### Claim 8 (depends on 3)

The method of claim 3, wherein each of the enzymes is a serine protease, a cysteine protease, a threonine protease, an aspartic protease, or a metalloprotease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the reporters are released via enzymatic cleavage.

### Claim 10 (depends on 3)

The method of claim 3, wherein the liver disease is non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), alcoholic liver disease, genetic liver diseases, autoimmune liver diseases, toxicity-induced liver disease, or metastatic liver cancer.

### Claim 11 (depends on 3)

The method of claim 3, wherein the proteases are selected from the group consisting of FAP, MMP2, ADAMTS2, FURIN, MMP14, GZMB, PRSS8, MMP8, ADAM12, CTSS, CTSA, CTSZ, CASP1, ADAMTS12, CTSD, CTSW, MMP11, MMP12, GZMA, MMP23B, MMP7, ST14, MMP9, MMP15, ADAMDEC1, ADAMTS1, GZMK, KLK11, MMP19, PAPPA, CTSE, PCSK5, and PLAU.

### Claim 12 (depends on 3)

The method of claim 3, further comprising the step of determining a stage of NASH.

### Claim 13 (depends on 1)

The method of claim 1, wherein the activity sensor comprises a multi-arm polyethylene glycol (PEG) scaffold and the reporters comprise polypeptides linked to the PEG scaffold.

### Claim 14

A composition for screening or diagnosis of liver disease, the composition comprising:
an activity sensor; and
a reporter releasably attached to the activity sensor,
wherein the reporter is released from the activity sensor in the liver in the presence of an enzyme that is differentially expressed in liver affected by a disease versus healthy liver.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the reporter is released from the activity sensor via enzymatic cleavage.

### Claim 16 (depends on 15)

The composition of claim 15, further comprising a plurality of the activity sensors, wherein each activity sensors has a plurality of the reporters releasably attached thereto, wherein the plurality of activity sensors are released by a plurality of enzymes that are differentially expressed in liver affected by the disease.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the plurality of enzymes are selected from the group consisting of FAP, MMP2, ADAMTS2, FURIN, MMP14, GZMB, PRSS8, MMP8, ADAM12, CTSS, CTSA, CTSZ, CASP1, ADAMTS12, CTSD, CTSW, MMP11, MMP12, GZMA, MMP23B, MMP7, ST14, MMP9, MMP15, ADAMDEC1, ADAMTS1, GZMK, KLK11, MMP19, PAPPA, CTSE, PCSK5, and PLAU.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the activity sensor comprises a molecular scaffold and the reporters comprise polypeptides linked to the scaffold.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the molecular scaffold comprises a polyethylene glycol (PEG) scaffold.

### Claim 20 (depends on 19)

The composition of claim 19, wherein PEG scaffold comprises a multi-arm PEG molecule of between about 30 and about 50 kDa.

### Claim 21 (depends on 16)

The composition of claim 16, wherein disease is non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), alcoholic liver disease, genetic liver diseases, autoimmune liver diseases, toxicity-induced liver disease, or metastatic liver cancer.

### Claim 22 (depends on 16)

The composition of claim 16, wherein the plurality of the reporters each comprise a polypeptide that includes a cleavage target of a protease that is differentially expressed in liver affected by the disease.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the plurality of reporters are selected to be cleaved by a set of enzymes that is differentially expressed in a liver affected by a certain stage of NASH.

### Claim 24 (depends on 23)

The composition of claim 23, wherein when the composition is injected into a subject, the plurality of activity sensors collect in the liver.

### Claim 25 (depends on 24)

The composition of claim 24, wherein when the plurality of activity sensors collect in a liver affected by NASH stage 2 or higher, the plurality of reporters are cleaved and released from the activity sensors.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the cleaved reporters comprise detectable polypeptides that enter circulation, are filtered from circulation at the kidneys, and are excreted in urine.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the detectable polypeptides can be detected by their mass-to-charge ratio.
